Brain scans reveal how cytisinicline may quiet smoking urges
NCT ID NCT06617312
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether the drug cytisinicline changes how the brain reacts to seeing smoking-related images in daily smokers who are not trying to quit. Sixty-four participants will receive either the drug or a placebo and undergo brain scans while watching videos of smoking and non-smoking cues. The goal is to understand the brain mechanisms behind reduced cravings, which could inform better treatments for tobacco use disorder.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cytisinicline
What this could lead to
If successful, this could reveal how cytisinicline changes brain activity related to smoking cravings, pointing toward a more effective quit-smoking aid.
What could go wrong
This is an early-phase lab study with only 64 participants who are not trying to quit, so results may not translate to real-world quitting success or apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOKING CESSATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California Los Angeles
RECRUITINGLos Angeles, California, 90049, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••